XOMA Corp (NASDAQ:XOMA) major shareholder Bvf Partners L. P/Il bought 21,141 shares of the business’s stock in a transaction on Thursday, November 15th. The stock was bought at an average cost of $13.31 per share, for a total transaction of $281,386.71. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.
Shares of XOMA stock opened at $14.07 on Tuesday. XOMA Corp has a 1 year low of $11.88 and a 1 year high of $37.25. The stock has a market capitalization of $119.61 million, a price-to-earnings ratio of 14.36 and a beta of 2.75. The company has a quick ratio of 5.38, a current ratio of 5.38 and a debt-to-equity ratio of 19.16.
XOMA (NASDAQ:XOMA) last announced its quarterly earnings results on Wednesday, November 7th. The biotechnology company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.40). XOMA had a negative return on equity of 267.64% and a negative net margin of 129.85%. The business had revenue of $0.90 million during the quarter, compared to the consensus estimate of $0.83 million. On average, research analysts predict that XOMA Corp will post -1.63 EPS for the current fiscal year.
Several equities analysts have weighed in on the company. HC Wainwright reissued a “buy” rating and issued a $49.00 target price on shares of XOMA in a research note on Friday, September 21st. S&P Equity Research cut their target price on XOMA from $18.74 to $16.26 in a research note on Tuesday, August 14th. Cowen reissued a “hold” rating on shares of XOMA in a research note on Thursday, November 8th. Wedbush reissued an “outperform” rating on shares of XOMA in a research note on Monday, September 17th. Finally, Zacks Investment Research lowered XOMA from a “hold” rating to a “sell” rating in a research note on Saturday, August 11th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and two have issued a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $28.07.
ILLEGAL ACTIVITY NOTICE: “XOMA Corp (XOMA) Major Shareholder Bvf Partners L. P/Il Purchases 21,141 Shares of Stock” was reported by WKRB News and is the sole property of of WKRB News. If you are reading this report on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this report can be read at https://www.wkrb13.com/2018/11/20/xoma-corp-xoma-major-shareholder-bvf-partners-l-p-il-purchases-21141-shares-of-stock.html.
XOMA Corporation engages in the discovery, development, and licensing of therapeutic antibodies in the United States, Europe, and the Asia Pacific. The company has a portfolio of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development.
Further Reading: Cost of Capital Explained
Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.